February 16, 2012 — Velomedix Inc., a clinical stage medical device company, announced it has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to evaluate the use of rapid therapeutic hypothermia for the treatment of patients suffering an acute myocardial infarction (AMI or heart attack).
